Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma (pages 758–767)
Brian I. Rini, Mark Stein, Pat Shannon, Simantini Eddy, Allison Tyler, Joe J. Stephenson Jr, Lorie Catlett, Bo Huang, Diane Healey and Michael Gordon
Version of Record online: 4 OCT 2010 | DOI: 10.1002/cncr.25639
On the basis of potential additive or synergistic immunostimulatory antitumor effects, this phase 1 study evaluated the combination of sunitinib and tremelimumab (CP-675206, an antibody against cytotoxic T lymphocyte-associated antigen 4) in patients with metastatic renal cell carcinoma. However, rapid-onset acute renal failure was observed unexpectedly in patients who received this combination, and further investigation of tremelimumab doses ≥6 mg/kg administered once every 12 weeks plus sunitinib 37.5 mg daily was not recommended.